Nilsine Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Nilsine Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Sell	3,532 -44	-1%	-$19.5K	0.12%	167
2026 Q1	$1.52M	Sell	3,576 -205	-5%	-$95.6K	0.12%	162
2025 Q4	$1.71M	Buy	3,781 +229	+6%	+$98.7K	0.15%	139
2025 Q3	$1.39M	Sell	3,552 -173	-5%	-$72.3K	0.13%	170
2025 Q2	$1.66M	Buy	3,725 +5	+0.1%	+$2.3K	0.17%	134
2025 Q1	$1.8M	Buy	3,720 +516	+16%	+$240K	0.2%	112
2024 Q4	$1.29M	Buy	3,204 +2	+0.1%	+$927	0.14%	162
2024 Q3	$1.49M	Sell	3,202 -248	-7%	-$119K	0.19%	130
2024 Q2	$1.62M	Sell	3,450 -31	-0.9%	-$13.5K	0.22%	116
2024 Q1	$1.46M	Sell	3,481 -71	-2%	-$30K	0.2%	128
2023 Q4	$1.45M	Sell	3,552 -1,760	-33%	-$650K	0.22%	118
2023 Q3	$1.85M	Buy	5,312 +1,093	+26%	+$382K	0.28%	94
2023 Q2	$1.48M	Buy	4,219 +39	+0.9%	+$13.1K	0.22%	114
2023 Q1	$1.32M	Buy	+4,180	New	+$1.25M	0.21%	125

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nilsine Partners's VRTX Position: Q2 2026 in Review

Nilsine Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q2 2026, selling an estimated $19.5K and leaving 3,532 shares worth $1.75M. The position accounts for 0.12% of the portfolio, ranked #167.

Nilsine Partners first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.85M in Q3 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Nilsine Partners held 3,532 shares of Vertex Pharmaceuticals worth $1.75M as of Q2 2026.
Nilsine Partners sold 44 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.5K.
Vertex Pharmaceuticals made up 0.12% of Nilsine Partners's portfolio in Q2 2026, its #167 holding.
Nilsine Partners first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Nilsine Partners's Vertex Pharmaceuticals position peaked at $1.85M in Q3 2023.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.